These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 20236129)

  • 21. [Indications of mTOR inhibitors in liver transplantation].
    Calmus Y; Dharancy S
    Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S245-6. PubMed ID: 20004329
    [No Abstract]   [Full Text] [Related]  

  • 22. Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects.
    Mahé E; Morelon E; Lechaton S; Drappier JC; de Prost Y; Kreis H; Bodemer C
    J Am Acad Dermatol; 2006 Jul; 55(1):139-42. PubMed ID: 16781309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A spectrophotometric assay for routine measurement of mammalian target of rapamycin activity in cell lysates.
    Dekter HE; Romijn FP; Temmink WP; van Pelt J; de Fijter JW; Smit NP
    Anal Biochem; 2010 Aug; 403(1-2):79-87. PubMed ID: 20417611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Antitumoral effect of proliferation signal inhibitors].
    Dumortier J
    Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S263-7. PubMed ID: 20004333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. mToR inhibitors-induced proteinuria: mechanisms, significance, and management.
    Letavernier E; Legendre C
    Transplant Rev (Orlando); 2008 Apr; 22(2):125-30. PubMed ID: 18631865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center.
    Rodríguez-Moreno A; Ridao N; García-Ledesma P; Calvo N; Pérez-Flores I; Marques M; Barrientos A; Sánchez-Fructuoso AI
    Transplant Proc; 2009; 41(6):2163-5. PubMed ID: 19715862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sirolimus in renal transplantation.
    Morath C; Arns W; Schwenger V; Mehrabi A; Fonouni H; Schmidt J; Zeier M
    Nephrol Dial Transplant; 2007 Sep; 22 Suppl 8():viii61-viii65. PubMed ID: 17890266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapamycin joins the aging fray: maybe Ponce de Leon visited Rapa Nui, not Florida.
    Sierra F
    J Gerontol A Biol Sci Med Sci; 2010 Jun; 65(6):577-9. PubMed ID: 20410142
    [No Abstract]   [Full Text] [Related]  

  • 29. The role of mTOR signaling in controlling mammalian life span: what a fungicide teaches us about longevity.
    Sharp ZD; Strong R
    J Gerontol A Biol Sci Med Sci; 2010 Jun; 65(6):580-9. PubMed ID: 20083554
    [No Abstract]   [Full Text] [Related]  

  • 30. Recent advances in the development of selective, ATP-competitive inhibitors of mTOR.
    Richard DJ; Verheijen JC; Zask A
    Curr Opin Drug Discov Devel; 2010 Jul; 13(4):428-40. PubMed ID: 20597028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional consequences of mTOR inhibition.
    Sudarsanam S; Johnson DE
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):31-40. PubMed ID: 20047144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
    Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. mTOR inhibitors in polycystic kidney disease.
    Watnick T; Germino GG
    N Engl J Med; 2010 Aug; 363(9):879-81. PubMed ID: 20581393
    [No Abstract]   [Full Text] [Related]  

  • 35. Side effects of sirolimus.
    Merkel S; Mogilevskaja N; Mengel M; Haller H; Schwarz A
    Transplant Proc; 2006 Apr; 38(3):714-5. PubMed ID: 16647452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Common occurrence of everolimus-associated aphthous stomatitis in Japanese heart transplant recipients.
    Sasaoka T; Kato TS; Oda N; Wada K; Komamura K; Asakura M; Hashimura K; Ishibashi-Ueda H; Nakatani T; Isobe M; Kitakaze M
    Transplant Proc; 2010 Nov; 42(9):3700-3. PubMed ID: 21094841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics.
    Dai B; Kong YY; Ye DW; Ma CG; Zhou X; Yao XD
    BJU Int; 2009 Oct; 104(7):1009-16. PubMed ID: 19389013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
    Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sirolimus--challenging current perspectives.
    Buhaescu I; Izzedine H; Covic A
    Ther Drug Monit; 2006 Oct; 28(5):577-84. PubMed ID: 17038868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].
    Ravaud A; Bernhard JC; Gross-Goupil M; Digue L; Ferriere JM
    Bull Cancer; 2010; 97():45-51. PubMed ID: 20418203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.